Drug Information

Drug General Information
Drug ID
D00JDL
Former ID
DIB010700
Drug Name
MGD006
Drug Type
Monoclonal antibody
Indication Acute lymphoblastic leukemia; Acute myeloid lymphoma [ICD9: 204.0, 556; ICD10:C91.0, C92.0] Phase 1 [544458], [889399]
Company
MacroGenics
Target and Pathway
Target(s) T-cell surface glycoprotein CD3 Target Info Modulator [544458]
Interleukin 3 receptor Target Info Modulator [544458]
KEGG Pathway Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Apoptosis
Jak-STAT signaling pathway
Hematopoietic cell lineage
NetPath Pathway IL5 Signaling Pathway
IL3 Signaling Pathway
Pathway Interaction Database IL3-mediated signaling events
Reactome GPVI-mediated activation cascade
G beta:gamma signalling through PI3Kgamma
Interleukin-3, 5 and GM-CSF signaling
RAF/MAP kinase cascade
Interleukin receptor SHC signaling
WikiPathways IL-3 Signaling Pathway
Interleukin-2 signaling
Interleukin-3, 5 and GM-CSF signaling
References
Ref 544458A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.
Ref 889399ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS
Ref 544458A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.